• Ask the Doctor- Interview with Dr. John L. Marshall

    In an interview with Cancer Wellness Magazine, Dr. John L. Marshall shares his thoughts on the rising rates of early-onset colorectal cancers.

    Category: News

  • ASCO’s recognition of molecular profiling in GI cancers as the “Advance of the Year”

    According to Dr. Louis M. Weiner, Professor and Director of Georgetown Lombardi Comprehensive Cancer Center, “ASCO’s recognition of molecular profiling in GI cancers as the ‘Advance of the Year’ validates the mission and work of Lombardi’s Ruesch Center for the Cure of GI Cancers. Since its founding over 10 years ago, the Ruesch Center has prioritized the science of precision medicine through education, building collaborative research networks, and dedicated funding all supporting precision medicine in GI cancers. ASCO’s selection of our collective progress reinforces and re-energizes us all. We are indebted to John Marshall, MD for his vision, energy, and wisdom in bringing this important initiative to life and then nurturing it.”

    Category: News

  • Precision Medicine, Targeted Therapy, and ZIP Codes: ASCO GI 2021

    The Doximity Op-Med, authored by Former Ruesch Center faculty member Mohamed Salem, provides an excellent review of a selection of ASCO GI-presented research. This article highlights his ongoing study, in collaboration with The Ruesch Center’s Marion Hartley and Georgetown’s Kristi Graves, into socioeconomic status and survival outcomes in patients with gastrointestinal cancers.

    Category: News

  • Factors to Consider When Prescribing 3L Colorectal Cancer Therapy

    John L. Marshall, MD discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology. According to Marshall, there are 3 or more medications to choose from when considering third line therapy including regorafenib (Stivarga) and TAS-102 (trifluridine and tipiracil, brand name Lonsurf. This space is also constantly evolving, with promising new combinations from Lonsurf.

    Category: News

  • Interview with Dr. John Marshall and Dr. Tony Shields on MI FOLFOXai™

    In this interview Dr. Marshall and Dr. Shields discuss the findings of their paper and how we can better predict which metastatic colorectal cancer patients will benefit from first-line FOLFOX+BV followed by FOLFIRI+BV or vice versa.

    Category: News

  • Ruesch Center Targets Gastrointestinal Cancers

    While her husband received treatment, Jeanne Ruesch saw firsthand the dishearteningly protracted pace of gastrointestinal cancer research. She was inspired by the care that she and her husband received from oncologist John Marshall, MD, but at the same time recognized a gaping need for a better understanding of GI cancers and how to treat them.

    Category: News

  • Disrupting the cellular process that promotes pancreatic cancer’s deadly growth

    In research part-funded by the Ruesch Center and published today in Gastroenterology, Georgetown’s Peran, Byers, et al. find a possible biomarker and mechanism for gemcitabine response in pancreas cancer.

    Category: News

  • OncLive® Partners with The Ruesch Center to Host the 11th Annual Ruesch Center Symposium

    Finding more cures for GI cancer will only come through innovative research, and we are so proud to be featuring both the most up-to-date science and the projects of tomorrow. And as a bonus, we will be premiering our new POWER program, a short course in precision medicine to close our knowledge gaps in this rapidly evolving field,” said John L. Marshall, M.D., director, The Ruesch Center for the Cure of GI Cancers.

    Category: News

  • Dr. Marshall Recognizes Need for Collaboration During Pancreatic Cancer Awareness Month

    In an interview with Targeted Oncology, John L. Marshall, MD, provided an overview of the evolution of treatments for patients with pancreatic cancer, as well as the current therapeutic approaches for these patients and what’s next for this treatment paradigm.

    Category: News

  • Oncology Peer Review On-The-Go: Molecular Profiling in Metastatic Colorectal Cancer

    This episode of “Oncology Peer Review On-The-Go” examines a review article published in the September issue of the journal ONCOLOGY. The article, “Molecular Profiling in Metastatic Colorectal Cancer,” was written by Samantha Armstrong, MD, Rita Malley, MS, and Benjamin Weinberg MD. For the article’s response perspective, CancerNetwork spoke with John Marshall, MD, of the Georgetown Lombardi Comprehensive Cancer Center. Dr. Marshall discussed the cost, quality of care, accessibility and more regarding molecular profiling and precision medicine.

    Category: News